SPCBoard, Specialty Pharma Certification Board, specialty pharma.#Specialty #pharma

Posted On May 12 2018 by

specialty pharma The CSP Program is now recognized by the National Commission for Certifying Agencies (NCCA) The CSP is now Accredited by the NCCA The Specialty Pharmacy Certification Board™ is developing unique and differentiated Certifications for Healthcare professionals that are relevant and meaningful to all Specialty Pharmacy therapeutic practices, and will promote new industry standards, with clarity. Specialty Pharmacy Certification Board The CSP™ credential will validate a pharmacist’s expertise in Specialty Pharmaceuticals, whether in Retail, Chain, Infusion, Mail Order, Hospital or alternative sites of care. It will benefit all practicing pharmacists by providing credibility, career advancement opportunities, enhanced placement opportunities, …


SPCBoard, Specialty Pharma Certification Board, specialty pharma.#Specialty #pharma

Posted On Mar 2 2018 by

specialty pharma The CSP Program is now recognized by the National Commission for Certifying Agencies (NCCA) The CSP is now Accredited by the NCCA The Specialty Pharmacy Certification Board™ is developing unique and differentiated Certifications for Healthcare professionals that are relevant and meaningful to all Specialty Pharmacy therapeutic practices, and will promote new industry standards, with clarity. Specialty Pharmacy Certification Board The CSP™ credential will validate a pharmacist’s expertise in Specialty Pharmaceuticals, whether in Retail, Chain, Infusion, Mail Order, Hospital or alternative sites of care. It will benefit all practicing pharmacists by providing credibility, career advancement opportunities, enhanced placement opportunities, …


SPCBoard, Specialty Pharma Certification Board, specialty pharma.#Specialty #pharma

Posted On Jan 15 2018 by

specialty pharma The CSP Program is now recognized by the National Commission for Certifying Agencies (NCCA) The CSP is now Accredited by the NCCA The Specialty Pharmacy Certification Board™ is developing unique and differentiated Certifications for Healthcare professionals that are relevant and meaningful to all Specialty Pharmacy therapeutic practices, and will promote new industry standards, with clarity. Specialty Pharmacy Certification Board The CSP™ credential will validate a pharmacist’s expertise in Specialty Pharmaceuticals, whether in Retail, Chain, Infusion, Mail Order, Hospital or alternative sites of care. It will benefit all practicing pharmacists by providing credibility, career advancement opportunities, enhanced placement opportunities, …


Tri Pharma – Your Preferred Pharmaceutical Wholesaler, specialty pharma.#Specialty #pharma

Posted On Jan 15 2018 by

Tri Pharma Trusted • Respected • Informative Specialty Pharmaceutical Wholesaler About Us Tri-Pharma is a specialty pharmaceutical wholesaler with a national reputation for integrity, excellence, leadership, and dependability. We deliver what you need, when you need it. Authorized Trading Partners Lean on our expertise and insight to successfully distribute your inventory. With over a century of collective experience, we can put our industry knowledge to work for you. Industry News Updates As a leader in the pharmaceutical wholesale industry, Tri-Pharma welcomes the opportunity to share valuable resources and updates. Check back often for the latest news. Client Testimonial: “My past …


Specialty Pharmacy News – Drug Store News #french #pharmaceutical #companies

Posted On Dec 26 2017 by

#pharmacy news # Specialty Pharmacy News Two recent unanimous approval recommendations from FDA advisory committees regarding biosimilars is a signal of growing scientific acceptance and understanding of the biosimilar regulatory pathway, suggested The National Law Review in a report Tuesday. The National Law Review has created a chart summarizing pending and approved BLAs for biosimilars using publicly available information, the publication noted, but there are still two barriers to entry. As biosimilars gain FDA approval, patent issues remain a barrier and the exorbitant R D cost prevent significant price disparities. Accordingly, insurers may be slow to add biosimilars to the …


Specialty Pharmacy News – Drug Store News #pharmaceutical #contract #manufacturer

Posted On Dec 19 2017 by

#pharmacy news # Specialty Pharmacy News Two recent unanimous approval recommendations from FDA advisory committees regarding biosimilars is a signal of growing scientific acceptance and understanding of the biosimilar regulatory pathway, suggested The National Law Review in a report Tuesday. The National Law Review has created a chart summarizing pending and approved BLAs for biosimilars using publicly available information, the publication noted, but there are still two barriers to entry. As biosimilars gain FDA approval, patent issues remain a barrier and the exorbitant R D cost prevent significant price disparities. Accordingly, insurers may be slow to add biosimilars to the …


Drug Channels: 2013 Pharmacy Market Share for Specialty Drugs – and the Biggest Players #pharmaceuticals #industry

Posted On Nov 26 2017 by

#pharmaceutical companies market share # Our research shows a booming market: In 2013, retail, mail, and specialty pharmacies dispensed about $63 billion in specialty pharmaceuticals. Specialty drugs accounted for 22% of total pharmacy industry revenues. Three companies Express Scripts, CVS Caremark, and Walgreens accounted for 63% of revenues from pharmacy-dispensed specialty drugs. The next three largest players had a combined share of about 5%. Read on for our market share estimates for the top players, observations on the market’s structure, and details of my panel discussion with specialty pharmacy leaders at next week s sPCMA Business Forum . THE NOMINEES …


Specialty Pharmacy News – Drug Store News #pharma #medical

Posted On Nov 24 2017 by

#pharmacy news # Specialty Pharmacy News Two recent unanimous approval recommendations from FDA advisory committees regarding biosimilars is a signal of growing scientific acceptance and understanding of the biosimilar regulatory pathway, suggested The National Law Review in a report Tuesday. The National Law Review has created a chart summarizing pending and approved BLAs for biosimilars using publicly available information, the publication noted, but there are still two barriers to entry. As biosimilars gain FDA approval, patent issues remain a barrier and the exorbitant R D cost prevent significant price disparities. Accordingly, insurers may be slow to add biosimilars to the …


Drug Channels: 2013 Pharmacy Market Share for Specialty Drugs – and the Biggest Players #real #pharma

Posted On Nov 9 2017 by

#pharmaceutical companies market share # Our research shows a booming market: In 2013, retail, mail, and specialty pharmacies dispensed about $63 billion in specialty pharmaceuticals. Specialty drugs accounted for 22% of total pharmacy industry revenues. Three companies Express Scripts, CVS Caremark, and Walgreens accounted for 63% of revenues from pharmacy-dispensed specialty drugs. The next three largest players had a combined share of about 5%. Read on for our market share estimates for the top players, observations on the market’s structure, and details of my panel discussion with specialty pharmacy leaders at next week s sPCMA Business Forum . THE NOMINEES …


Specialty Pharmacy News – Drug Store News #infinity #pharma

Posted On Nov 5 2017 by

#pharmacy news # Specialty Pharmacy News Two recent unanimous approval recommendations from FDA advisory committees regarding biosimilars is a signal of growing scientific acceptance and understanding of the biosimilar regulatory pathway, suggested The National Law Review in a report Tuesday. The National Law Review has created a chart summarizing pending and approved BLAs for biosimilars using publicly available information, the publication noted, but there are still two barriers to entry. As biosimilars gain FDA approval, patent issues remain a barrier and the exorbitant R D cost prevent significant price disparities. Accordingly, insurers may be slow to add biosimilars to the …